Hemodialysis cost in Tehran, Iran

Hemodialysis International

Volumn 12, Issue 4, 2008, Pages 492-498

  Mahdavi Mazdeh, Mitra ^a,e   Zamani, Mozafar ^b   Zamyadi, Mahnaz ^b   Rajolani, Hamid ^b   Tajbakhsh, Keyvan ^c   Heidary Rouchi, Alireza ^b   Aghighi, Mahammad ^b   Mahdavi, Azita ^d  

^a UNIVERSITY OF TEHRAN   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c Medical Service Insurance Organization   (Iran)

^d National Behzisti Organization

^e Emam Hospital   (Iran)

Author keywords

Cost; Developing world; ESRD; Hemodialysis; Iran

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CAREGIVER SUPPORT; CLINICAL PRACTICE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMODIALYSIS; HUMAN; IRAN; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PREVALENCE; REFERENCE VALUE; RENAL REPLACEMENT THERAPY; RISK REDUCTION; SALARY; TRAFFIC AND TRANSPORT; TREATMENT DURATION;

DEVELOPING COUNTRIES; DRUG COSTS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INCIDENCE; IRAN; KIDNEY FAILURE, CHRONIC; MORBIDITY; PREVALENCE; RENAL DIALYSIS; SALARIES AND FRINGE BENEFITS;

EID: 53549085722     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00313.x     Document Type: Article

References (33)

1. Mahdavi-Mazdeh M, Zamyadi M, Nafar M. Assessment of management and treatment response in hemodialysis patients in Tehran province, Iran. Nephrol Dial Transplant. 2008; 23: 288-293.
2. Zatz R, Romão JE Jr. End-stage renal failure and national resources: The Brazilian experience. Ren Fail. 2006; 28: 627-629.
3. Klarenbach SW. Economic evaluation in renal disease. J Nephrol. 2007; 20: 251-259.
4. Adomakoh S, Adi C, Fraser H, Nicholson G. Dialysis in Barbados: The cost of haemodialysis provision at the Queen Elizabeth Hospital. Rev Panam Salud Publica/Pan Am J Public Health. 2004; 16: 350-355.
5. Kaitelidou D, Ziroyanis PN, Maniadakis N, Liaropoulos L. Economic evaluation of hemodialysis: Implications for technology assessment in Greece. Int J Technol Assess Health Care. 2005; 21: 40-46.
6. Foley RN, Collins AJ. End-stage renal disease in the United States: An update from the United States renal data system. J Am Soc Nephrol. 2007; 18: 2644-2648.
7. Straube BM. Commentary. The imperative for change in the US health care payment and delivery systems are clear. Adv Chronic Kidney Dis. 2008; 15: 7-9.
8. Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med. 2006; 354: 997-999.
9. Lockridge RS Jr. The direction of end-stage renal disease reimbursement in the United States. Semin Dial. 2004; 17: 125-130.
10. Mahdavi-Mazdeh M, Heidary-Rouchi A, Aghighi M, Rajolani H. Organ and tissue transplantation in Iran. Saudi J Kidney Dis Transpl. 2008; 19: 127-131.
11. Sisca S, Pizzarelli F. Cost-benefit analysis and choice of dialysis treatment in Italy. Dial Transplant. 2002; 31: 382-387.
12. Hooi LS, Lim TO, Goh A, et al. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Nephrology. 2005; 10: 25-32.
13. Tediosi F, Bertolini G, Parazzini F, Mecca G, Garattini L. Cost analysis of dialysis modalities in Italy. Health Serv Manage Res. 2001; 14: 9-17.
14. Imerman M, Otto D. Preliminary market and cost analysis of a five-station hemodialysis facility in Marengo, IA. Iowa State University Department of Economics. February 25, 2004.
15. Salonen T, Reina T, Oksa H, Sintonen H, Pasternack A. Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis. 2003; 42: 1228-1238.
16. Perico N, Plata R, Anabaya A, et al. Strategies for national health care systems in emerging countries: The case of screening and prevention of renal disease progression in Bolivia. Kidney Int. 2005; 68(Suppl 97): S87-S94.
17. Pacheco A, Saffie A, Torres R, et al. Cost/utility study of peritoneal dialysis and hemodialysis in Chile. Perit Dial Int. 2007; 27: 359-363.
18. Abraham G, Moorathy AV, Aggarwal V. Chronic kidney disease: A silent epidemic in Indian subcontinent - Strategies for management. J Indian Med Assoc. 2006; 104: 689-691.
19. Imai E, Yamagata K, Iseki K, et al. Kidney disease screening program in Japan: History, outcome, and perspectives. Clin J Am Soc Nephrol. 2007; 2: 1360-1366.
20. Stewart JH, McCredie MR, Williams SM, Jager KJ, Trpeski L, McDonald SP. ESRD incidence study group: Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrology. 2007; 12: 520-527.
21. Sehgal AR. The incremental cost of providing adequate hemodialysis. Dial Transplant. 2003; 32: 526-531.
22. Deoreo PB. How dialysis is paid for: What the dialysis medical director should know, and why. Semin Dial. 2008; 21: 58-62.
23. Batieha A, Abdallah S, Maghaireh M, et al. Epidemiology and cost of haemodialysis in Jordan. East Mediterr Health J. 2007; 13: 654-663.
24. Lamas J, Alonso M, Saavedra J, Garcia-Trio G, Rionda M, Ameijeiras M. Costs of chronic dialysis in a public hospital: Myths and realities. Nefrologia. 2001; 21: 283-294.
25. Benain JP, Faller B, Briat C, et al. Cost of dialysis in France. Nephrol Ther. 2007; 3: 96-106.
26. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002; 40: 611-622.
27. Bruns FJ, Seddon P, Saul M, Zeidel ML. The cost of caring for end-stage kidney disease patients: An analysis based on hospital financial transaction records. J Am Soc Nephrol. 1998; 9: 884-890.
28. Barsoum RS. Overview: End-stage renal disease in the developing world. Artif Organs. 2002; 26: 737-746.
29. Roderick P, Nicholson T, Armitage A, et al. An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. Health Technol Assess. 2005; 9: 1-178.
30. De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: Costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant. 1999; 14(Suppl 6): 31-41.
31. Manns B, Lee H, Taub K, et al. Summary of: Cost analysis of ongoing care of patients with end-stage renal disease: What are the important determinants? Available from: http://www.health.gov.ab.ca/key/ 25_summary.pdf (accessed date: March 2003).
32. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006; 332: 563-564.
33. Levey AS, Andreoli SP, Dubose T, Provenzano R, Collins AJ. Chronic kidney disease, common, harmful, and treatable - World Kidney Day 2007. Clin J Amer Soc Nephrol. 2007; 2: 401-405.